Home > Insider Trading > Filing (0001099910-12-000246)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1126234	Newlink Genetics Corp	NLNK	Pharmaceutical Preparations (2834)	421491350

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1261262	Jr H Gordon Link	C/O Newlink Genetics Corporation 2503 South Loop Dr., Suite 5100 Ames IA 50010	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2012-10-15	5,500	$2.10	9,813	No	4	M	Direct
Common Stock	Disposition	2012-10-15	779	$14.84	9,034	No	4	F	Direct
Common Stock	Disposition	2012-10-15	4,721	$14.84	4,313	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	F	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2012-10-15	5,500	$0.00	5,500	$2.10

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2018-08-05	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	4,313	Direct

Footnotes

Includes 813 shares acquired under the NewLink Genetics Corporation 2010 Employee Stock Purchase Plan on June 29, 2012.
Represents a "net exercise" of outstanding stock options. The reporting person received 4,721 shares of common stock on net exercise of option to purchase 5,500 shares of common stock. The reporting person forfeited 779 shares of common stock underlying the option in payment of the exercise price, using the weighted average stock price from the sale of $14.8411.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.70 to $15.065, inclusive. The reporting person undertakes to provide to the issuer, any security holder of issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on 10/1/2012.
1/4th of the shares vest on August 4, 2009, which is one year after the vesting commencement date. 1/48th of the shares vest monthly thereafter over the next three years.